Nevertheless, it remains crucial to distinguish AKT1WT and AKT1E17K status in further translational and clinical studies when targeting SVIL‐AS1 in combination with PI3K‐AKT1 inhibitors for more precise evaluation of treatment responses of cancer patients. This evidence concerns the gene SVIL and cancer.